Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments
10:35am, Friday, 20'th Mar 2026
GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term growth.
Glaukos Corporation (NYSE:GKOS) Given Average Rating of “Moderate Buy” by Brokerages
02:44am, Friday, 20'th Mar 2026
Glaukos Corporation (NYSE: GKOS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the sixteen brokerages that are currently covering the stock, Marketbeat Ratings repor
Why Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report?
12:31pm, Thursday, 19'th Mar 2026
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
07:00am, Thursday, 19'th Mar 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Capital International Investors Buys 264,971 Shares of Glaukos Corporation $GKOS
04:13am, Friday, 13'th Mar 2026
Capital International Investors raised its stake in Glaukos Corporation (NYSE: GKOS) by 107.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commis
Citigroup Inc. Sells 34,689 Shares of Glaukos Corporation $GKOS
03:40am, Monday, 09'th Mar 2026
Citigroup Inc. lessened its holdings in shares of Glaukos Corporation (NYSE: GKOS) by 61.3% in the third quarter, according to its most recent filing with the SEC. The firm owned 21,912 shares of the
Glaukos (NYSE:GKOS) Director Aimee Weisner Sells 15,000 Shares
04:49am, Tuesday, 24'th Feb 2026
Glaukos Corporation (NYSE: GKOS - Get Free Report) Director Aimee Weisner sold 15,000 shares of the company's stock in a transaction on Thursday, February 19th. The shares were sold at an average pric
Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook
11:55am, Wednesday, 18'th Feb 2026
GKOS posts 36% Q4 revenue jump, raises 2026 sales outlook to $600-$620M as iDose TR and Epioxa fuel growth despite wider loss.
These Analysts Boost Their Forecasts On Glaukos Following Q4 Results
09:34am, Wednesday, 18'th Feb 2026
Glaukos Corp (NYSE: GKOS) reported mixed results for the fourth quarter on Tuesday.
Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript
11:14pm, Tuesday, 17'th Feb 2026
Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript
Glaukos (GKOS) Reports Q4 Earnings: What Key Metrics Have to Say
07:01pm, Tuesday, 17'th Feb 2026
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compar
Glaukos (GKOS) Reports Q4 Loss, Beats Revenue Estimates
06:25pm, Tuesday, 17'th Feb 2026
Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.4 per share a year ago.
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Tuesday, 17'th Feb 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Comparing Glaukos (NYSE:GKOS) & Inogen (NASDAQ:INGN)
02:59am, Thursday, 12'th Feb 2026
Glaukos (NYSE: GKOS - Get Free Report) and Inogen (NASDAQ: INGN - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the st
Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy?
11:00am, Tuesday, 10'th Feb 2026
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
